ANNX (Annexon Inc.) רווח למניה ב-12 החודשים האחרונים

The price action history of Annexon, Inc. (ANNX) demonstrates an EPS of 26.40. Annexon, Inc. (ANNX) develops neurological drugs under the supervision of experienced funds, ensuring the transparency of research data. The business relies on an autonomous development cycle that remains independent of global crises and serves as a defensive asset. However, fierce competition from industry behemoths acquiring startups creates significant risks for the issuer's market share.
annexonbio.com - פילוחים אנליטיים ומדדי מפתח (ANNX)

EPS (TTM) growth measures the percentage change in net income per share over the last twelve months, revealing profitability trends. By analyzing year-over-year changes in EPS (TTM), an investor can detect a fading operational momentum prior to official reports. This metric discounts capital management efficiency and the speed of business scaling. For Annexon, Inc. (ANNX), this reflects financial resilience during the development of complement system inhibitors for the therapy of neurodegenerative diseases.